California Allergy and Asthma Medical Group + Research Center

Los Angeles, California 90025

0 studies enrolling now · 3 studies all time

What they study most

Atopic Dermatitis, Chronic Spontaneous Urticaria

Studies at this site

• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. — Completed
• A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria — Stopped early